Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Jul

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy

Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

Emergency Hospital Admission Accounts for 40 of Ovarian Cancer Diagnoses in England

Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases